Pfizer-BioNTech Increased Its Production Target to 2 Billion Doses

Pfizer-BioNTech, the pharmaceutical companies that developed the coronavirus vaccine, increased its production target to 2 billion doses. The companies reported that they increased their production capacity in 2021 to 2 billion doses of vaccine. Presenting on Monday, BioNTech stated that the partners aim to manage the doses demanded by countries around the world and that the company partners have committed to more than half of the targeted production capacity of 2 billion doses. In the presentation, it was noted that a new production facility in Marburg, Germany, which is expected to start operations at the end of February, can produce 750 million doses of vaccine annually. The previous production target for 2021 was determined as 1.3 billion doses.